(Reuters) – Shares of Novavax (NASDAQ:) Inc surged almost 20% Wednesday, after advisors to Food and Drug Administration unanimously supported the use COVID-19 vaccination. This brings the shot closer to a U.S. launch.

After concerns raised by the Heath Regulator’s reviewers about heart inflammation after vaccinations, the stock fell around 20% Friday.

The voting of the advisors outside – 21 in favor, one against, and 1 abstention- suggests that FDA may soon approve the fourth vaccine. Novavax believes it will be the vaccine of choice for vaccine skeptics.

Stanley Erck, Novavax chief executive officer, said Tuesday that the positive vote “acknowledges both the strength of our data as well the importance of a Covid-19-based vaccine”.

Analysts said that Novavax is pleased with the FDA panel’s vote. It reduces uncertainty surrounding a vaccine, which had been on an extended path to authorisation.

Roger Song, a Jefferies analyst, said that the instances of severe heart inflammation would be alarming, even though it is concerning. He also warned about rival mRNA vaccinations. Moderna (NASDAQ) Inc Pfizer (NYSE:).

Mani Foroohar, a SVB Securities analyst stated that the vote is a challenge to the dominant position of mRNA vaccins on the COVID-19 marketplace.

Before the vaccine can be made available to the public, it must first be approved by the FDA.

Novavax shares rose 19% to $56.59, just before the bell.